The Cancer Injections: Chester Southam and the Study That Changed the Law on Informed Consent

In 1963, three junior physicians at the Jewish Chronic Disease Hospital in Brooklyn walked out of their jobs rather than participate in an experiment their superior had asked them to help conduct. The experiment involved injecting elderly, debilitated patients with live cancer cells. The patients had not been told what was being injected. They had not been told they were participating in research. They had been told, if they were told anything at all, that they were receiving a routine injection.

The three doctors, Avir Kagan, David Leichter, and Perry Fersko, refused. One of them described what was being proposed in terms that invoked the most extreme recent precedent: it was, he said, Nazi medicine. They reported what they knew to the New York State Board of Regents and to a hospital board member who was also an attorney. What followed was one of the most consequential episodes in the development of modern informed consent law in the United States.

A Decade of Injections

Chester Southam was a virologist and cancer researcher at the Sloan-Kettering Institute in New York City, one of the country’s most prestigious cancer research centers. He was also the kind of scientist whose career trajectory was characterised by genuine intelligence applied with an insufficient degree of ethical reflection. His research interest in the 1950s was in how the immune system responds to foreign cancer cells, a question with real clinical relevance: understanding why some patients reject transplanted tumours while others do not was considered a potentially important avenue toward cancer treatment.

To pursue this question, Southam began injecting live HeLa cancer cells, derived from the famous cell line originally taken from Henrietta Lacks, into patients. He started with terminally ill cancer patients, reasoning that they were already ill and that the injections posed limited additional risk. The injections produced nodules under the skin that grew for a period before the immune system responded and eliminated them, or, in some cases, did not. Southam removed the nodules when they grew, tracked the immune response, and collected data.

From 1954 onward, he expanded the program. He recruited prisoners at the Ohio State Penitentiary who, being healthy, showed more robust immune responses. He injected cancer cells into more than 600 people over the following decade. If he explained to patients what was being injected, he described it as a test for cancer rather than as the injection of live cancer cells from another person. Most patients were not told even that much. They were not told they were research subjects. They were not asked for their consent to participate in a study.

Brooklyn, 1963

In 1963, Southam approached Emanuel Mandel, the director of medicine at the Jewish Chronic Disease Hospital, and arranged to conduct his injections on the hospital’s patients. The hospital served elderly patients with chronic illnesses. Many had impaired cognition. Many did not speak English. Southam wanted to study whether the debilitated state of chronically ill patients affected their immune response to cancer cells.

The three Jewish physicians who refused to participate brought what they knew to the New York State Board of Regents. The Regents investigated and found Southam guilty of fraud, deceit, and unprofessional conduct. He was placed on probation for one year. His medical license was not revoked. He was not criminally charged.

Two years after his probation ended, the American Association for Cancer Research elected him its president.

The Legal Legacy

The Southam case did not end Southam’s career, but it did accelerate a shift in American law and policy toward the explicit recognition of patient autonomy in research contexts. The requirement that research subjects be told they are participating in research, told what the research involves, and asked to give voluntary informed consent, had been articulated in the Nuremberg Code since 1947. American research institutions had not consistently applied it. The controversy generated by the Southam case, alongside the simultaneous public debate about the Tuskegee study and the Willowbrook hepatitis experiments, contributed directly to the development of the National Research Act of 1974, which established the institutional review board system that now governs human subjects research in the United States.

The principle is simple enough to state in a sentence: a person cannot consent to something they do not know is happening. Southam’s patients had not consented to receiving cancer cells, because they had not been told that was what was happening. Their signatures on general hospital admission forms, or their absence of objection to an injection they were told was routine, did not constitute consent to participate in a cancer immunology study. That clarity, obvious in retrospect, required a federal regulatory architecture to enforce.

When asked why he had not simply injected himself with the cancer cells to test the procedure before asking patients to undergo it, Southam reportedly said that there were relatively few skilled cancer researchers, and it seemed wasteful to take even a small risk with one’s own health. The statement captures something important about how the researchers who conducted this era’s unethical experiments understood the relationship between their own persons and the persons of their subjects. The calculus was not always malicious. It was often simply a very precise failure to recognise other people as equally important.

TL;DR: Key Facts and Why This Case Matters

Who was Chester Southam?

Chester Southam was a virologist and cancer researcher at the Sloan-Kettering Institute in New York City who, from the mid-1950s through 1963, injected live cancer cells (HeLa cells) into more than 600 people, including terminally ill cancer patients, healthy prisoners at the Ohio State Penitentiary, and elderly chronically ill patients at the Jewish Chronic Disease Hospital in Brooklyn, without informing most of them what was being injected or that they were participating in research.

How was he caught and what were the consequences?

Three physicians at the Jewish Chronic Disease Hospital refused to participate in his 1963 injection program and reported him to the New York State Board of Regents and a hospital board member who was an attorney. The Regents found Southam guilty of fraud, deceit, and unprofessional conduct and placed him on one year’s probation. No criminal charges were brought. Two years after his probation, the American Association for Cancer Research elected him its president.

What was the legal and ethical significance?

The Southam case became a landmark in the development of American research ethics regulation. The refusal of three junior physicians to participate in non-consensual human experimentation, and their decision to report rather than comply, demonstrated that accountability in research ethics could begin with individual clinicians. The case contributed, alongside Tuskegee and Willowbrook, to the political pressure that produced the National Research Act of 1974 and the institutional review board system governing human subjects research in the United States.

Why does this case matter?

The Southam case illustrates three things that remain relevant: that prestigious institutions do not insulate researchers from ethical failure; that the consent obtained through silence, or through misdescription of a procedure, is not consent; and that individual acts of professional courage by junior medical staff can, when directed at the right institutions, produce systemic change. The three physicians who refused were not senior figures with institutional protection. They resigned and went public. Their decision changed the law.